Tizanidine Transdermal Patch Using Free Base and Polymer Matrix
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current transdermal therapeutic systems (TTS) for tizanidine administration face challenges such as complex formulations, inadequate adhesiveness, and storage stability issues, particularly with tizanidine hydrochloride, which does not permeate through the skin effectively, while tizanidine free base permeation is insufficient for sustained release.
Innovation Solution
A TTS comprising a tizanidine-containing layer with tizanidine in its free base form, combined with a polar polymer, a nonpolar polymer, and a fatty acid, along with an additive like lauryl lactate, to enhance skin permeation and stability, achieving a simpler structure and consistent quality for prolonged drug release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If tizanidine hydrochloride is used in the TTS formulation, then the formulation can be stable during storage, but the active ingredient does not permeate through the skin effectively
Solution Approach 1:
The patent changes the chemical form of tizanidine from hydrochloride salt to free base form, fundamentally altering its permeation properties. This parameter change enables the active ingredient to permeate through the skin while maintaining formulation stability through careful selection of polar and nonpolar polymers as excipients.
2Ease of manufacture
If tizanidine free base is used to improve skin permeation, then permeation is achieved, but the formulation becomes complex with more than 15 components
Solution Approach 1:
The patent extracts and eliminates unnecessary excipients from the formulation, reducing the component count from more than 15 to a simpler composition. This is achieved by carefully selecting only the essential polar polymer, nonpolar polymer, and fatty acid needed for permeation and stability, removing redundant components.
Solution Approach 2:
The patent uses a composite material approach by combining specific polar polymers and nonpolar polymers in a defined ratio, creating an effective formulation system that achieves permeation and stability goals with fewer components rather than using many individual excipients.
3Ease of manufacture
If a complex TTS formulation is used to achieve skin permeation, then permeation is achieved, but the adhesiveness of the tizanidine-containing layer becomes unsatisfactory
Solution Approach 1:
The patent optimizes the polymer composition parameters, specifically the ratio of polar to nonpolar polymers, to achieve both permeation and adhesiveness. By adjusting these compositional parameters, the formulation achieves satisfactory adhesive strength while maintaining effective skin permeation capabilities.
4Ease of manufacture
If tizanidine free base is used to achieve permeation, then some permeation occurs, but the permeation rate is insufficient for sustained release over 72 hours
Solution Approach 1:
The patent employs a composite material system combining specific polar polymers and nonpolar polymers in optimized ratios. This composite approach creates a matrix that controls the release kinetics of tizanidine, enabling sustained permeation over 72 hours by regulating the diffusion rate through the polymer network.
Solution Approach 2:
The patent optimizes the molecular weight, composition ratio, and cross-linking degree of the polymers to control the release rate. By adjusting these parameters, the formulation achieves a permeation rate that maintains therapeutic levels over the required 72-hour sustained release period.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The proposed TTS provides a therapeutically effective and sustained release of tizanidine over at least 72 hours with improved permeation rates and active-agent utilization, suitable for treating conditions like spasticity and pain, while being easier to manufacture and maintain consistent quality.
Implementation Method 1
tizanidine in the form of its free base slightly permeates through the skin
Implementation Method 2
at least one fatty acid... to enhance skin permeation
Data Source
AI summary
The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of tizanidine.